FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016088019> ?p ?o ?g. }

• W2016088019 endingPage "510" @default.
• W2016088019 startingPage "503" @default.
• W2016088019 abstract "Summary The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia (Ph+ ALL) treated with imatinib‐combined chemotherapy. Here we report the results of prospective MRD monitoring in 100 adult patients. Three hundred and sixty‐seven follow‐up bone marrow samples, collected at predefined time points during a uniform treatment protocol, were analysed for BCR‐ABL1 transcripts by quantitative reverse transcription polymerase chain reaction. Ninety‐seven patients (97%) achieved complete remission (CR), and the relapse‐free survival (RFS) rate was 46% at 3 years. Negative MRD at the end of induction therapy was not associated with longer RFS or a lower relapse rate ( P = 0·800 and P = 0·964 respectively). Twenty‐nine patients showed MRD elevation during haematological CR. Of these, 10 of the 16 who had undergone allogeneic haematopoietic stem cell transplantation (HSCT) in first CR were alive without relapse at a median of 2·9 years after transplantation, whereas 12 of the 13 who had not undergone allogeneic HSCT experienced a relapse. These results demonstrate that, in Ph+ ALL patients treated with imatinib‐combined chemotherapy, rapid molecular response is not associated with a favourable prognosis, and that a single observation of elevated MRD is predictive of subsequent relapse, but allogeneic HSCT can override its adverse effect." @default.
• W2016088019 created "2016-06-24" @default.
• W2016088019 creator A5000733045 @default.
• W2016088019 creator A5010994282 @default.
• W2016088019 creator A5013146671 @default.
• W2016088019 creator A5017994748 @default.
• W2016088019 creator A5018101881 @default.
• W2016088019 creator A5024134742 @default.
• W2016088019 creator A5028451977 @default.
• W2016088019 creator A5035714481 @default.
• W2016088019 creator A5045270299 @default.
• W2016088019 creator A5062828203 @default.
• W2016088019 creator A5063488239 @default.
• W2016088019 creator A5066277266 @default.
• W2016088019 creator A5067597137 @default.
• W2016088019 creator A5070702322 @default.
• W2016088019 creator A5070745575 @default.
• W2016088019 creator A5071023244 @default.
• W2016088019 creator A5084326036 @default.
• W2016088019 creator A5084655190 @default.
• W2016088019 creator A5084880219 @default.
• W2016088019 creator A5085637628 @default.
• W2016088019 date "2008-10-22" @default.
• W2016088019 modified "2023-10-10" @default.
• W2016088019 title "Prospective monitoring of <i>BCR‐ABL1</i> transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapy" @default.
• W2016088019 cites W1644813534 @default.
• W2016088019 cites W1984877560 @default.
• W2016088019 cites W1986395681 @default.
• W2016088019 cites W1993860626 @default.
• W2016088019 cites W1994309500 @default.
• W2016088019 cites W1998660089 @default.
• W2016088019 cites W2000116184 @default.
• W2016088019 cites W2005282952 @default.
• W2016088019 cites W2010474569 @default.
• W2016088019 cites W2014804837 @default.
• W2016088019 cites W2019471283 @default.
• W2016088019 cites W2023595115 @default.
• W2016088019 cites W2039201527 @default.
• W2016088019 cites W2054075974 @default.
• W2016088019 cites W2054251966 @default.
• W2016088019 cites W2089360398 @default.
• W2016088019 cites W2099616647 @default.
• W2016088019 cites W2105098746 @default.
• W2016088019 cites W2105435030 @default.
• W2016088019 cites W2109388187 @default.
• W2016088019 cites W2110661347 @default.
• W2016088019 cites W2117730045 @default.
• W2016088019 cites W2134091917 @default.
• W2016088019 cites W2137520438 @default.
• W2016088019 cites W2139499066 @default.
• W2016088019 cites W2147572934 @default.
• W2016088019 cites W2148854558 @default.
• W2016088019 cites W2151069914 @default.
• W2016088019 cites W2153400118 @default.
• W2016088019 cites W2153701773 @default.
• W2016088019 cites W2162801973 @default.
• W2016088019 cites W2249492217 @default.
• W2016088019 cites W2290043227 @default.
• W2016088019 cites W2313577290 @default.
• W2016088019 cites W4232666751 @default.
• W2016088019 doi "https://doi.org/10.1111/j.1365-2141.2008.07377.x" @default.
• W2016088019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18986386" @default.
• W2016088019 hasPublicationYear "2008" @default.
• W2016088019 type Work @default.
• W2016088019 sameAs 2016088019 @default.
• W2016088019 citedByCount "48" @default.
• W2016088019 countsByYear W20160880192012 @default.
• W2016088019 countsByYear W20160880192013 @default.
• W2016088019 countsByYear W20160880192014 @default.
• W2016088019 countsByYear W20160880192015 @default.
• W2016088019 countsByYear W20160880192016 @default.
• W2016088019 countsByYear W20160880192017 @default.
• W2016088019 countsByYear W20160880192018 @default.
• W2016088019 countsByYear W20160880192019 @default.
• W2016088019 countsByYear W20160880192022 @default.
• W2016088019 countsByYear W20160880192023 @default.
• W2016088019 crossrefType "journal-article" @default.
• W2016088019 hasAuthorship W2016088019A5000733045 @default.
• W2016088019 hasAuthorship W2016088019A5010994282 @default.
• W2016088019 hasAuthorship W2016088019A5013146671 @default.
• W2016088019 hasAuthorship W2016088019A5017994748 @default.
• W2016088019 hasAuthorship W2016088019A5018101881 @default.
• W2016088019 hasAuthorship W2016088019A5024134742 @default.
• W2016088019 hasAuthorship W2016088019A5028451977 @default.
• W2016088019 hasAuthorship W2016088019A5035714481 @default.
• W2016088019 hasAuthorship W2016088019A5045270299 @default.
• W2016088019 hasAuthorship W2016088019A5062828203 @default.
• W2016088019 hasAuthorship W2016088019A5063488239 @default.
• W2016088019 hasAuthorship W2016088019A5066277266 @default.
• W2016088019 hasAuthorship W2016088019A5067597137 @default.
• W2016088019 hasAuthorship W2016088019A5070702322 @default.
• W2016088019 hasAuthorship W2016088019A5070745575 @default.
• W2016088019 hasAuthorship W2016088019A5071023244 @default.
• W2016088019 hasAuthorship W2016088019A5084326036 @default.
• W2016088019 hasAuthorship W2016088019A5084655190 @default.
• W2016088019 hasAuthorship W2016088019A5084880219 @default.
• W2016088019 hasAuthorship W2016088019A5085637628 @default.
• W2016088019 hasConcept C104317684 @default.

• next